• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ACL
Click for more information
2.31% $3.54

AUSTRALIAN CLINICAL LABS LIMITED - Announcements

Market Cap $708.4M  ! watchlist Created with Sketch. Add to my watchlist

Australian Clinical Labs Limited is a private provider of pathology services. Its... Australian Clinical Labs Limited is a private provider of pathology services. Its laboratories perform a range of pathology tests each year for a range of clients, including doctors, specialists, patients, hospitals, and corporate clients. It performs a range of services for doctors, patients, and corporate clients, including routine pathology tests, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology and cytopathology, hematology, allergy and immunology, serology and microbiology, infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing. Its specialist services include molecular cancer services, obstetrics and gynecology, pharmacogenetic testing, gastroenterology, and hospital services. It has operations in Victoria, New South Wales, Western Australia, South Australia, Queensland, and the Northern Territory.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
ACL Ceasing to be a substantial holder from MS19/09/24
ACL Ceasing to be a substantial holder19/09/24
ACL Change in substantial holding from MUFG19/09/24
ACL Change in substantial holding19/09/24
ACL Becoming a substantial holder from MS19/09/24
ACL Initial Director's Interest Notices x 205/03/19
ACL Final Director's Interest Notices x 205/03/19
ACL Changes to the Board of Directors05/03/19
ACL Appendix 4D and Half Year ReportPRICE SENSITIVE27/02/19
ACL Appendix 4C - QuarterlyPRICE SENSITIVE18/01/19
ACL Results of Annual General Meeting27/11/18
ACL Notice of Annual General Meeting/Proxy Form26/10/18
ACL Appendix 4C - QuarterlyPRICE SENSITIVE19/10/18
ACL Response to ASX Price QueryPRICE SENSITIVE17/10/18
ACL Appendix 4G and Corporate Governance Statement30/08/18
ACL Appendix 4E and 2018 Annual ReportPRICE SENSITIVE30/08/18
ACL Appendix 4C - QuarterlyPRICE SENSITIVE23/07/18 download Created with Sketch. 198.16KB
ACL Final Director's Interest Notice06/06/18 download Created with Sketch. 152.41KB
ACL Initial Director's Interest Notice06/06/18 download Created with Sketch. 154.9KB
ACL Changes to the Board of Directors06/06/18 download Created with Sketch. 166.79KB
ACL Response to ASX Price QueryPRICE SENSITIVE09/05/18
ACL Appendix 4C - QuarterlyPRICE SENSITIVE24/04/18
ACL Appendix 4D and Half Year ReportPRICE SENSITIVE21/02/18
ACL Appendix 4C - QuarterlyPRICE SENSITIVE25/01/18
ACL Ceasing to be a substantial holder08/01/18
ACL Change of Director's Interest Notices x208/01/18
ACL Response to ASX Price QueryPRICE SENSITIVE03/01/18
ACL Results of Annual General Meeting28/11/17
ACL Appendix 4C - QuarterlyPRICE SENSITIVE27/10/17
ACL Notice of Annual General Meeting/Proxy Form25/10/17
ACL Appendix 4G and Corporate Governance Statement23/08/17
ACL Appendix 4E and 2017 Annual ReportPRICE SENSITIVE23/08/17
ACL Appendix 4C - QuarterlyPRICE SENSITIVE27/07/17
ACL Change of Director's Interest Notice07/07/17
ACL Appendix 4C - QuarterlyPRICE SENSITIVE26/04/17
ACL Half Yearly Report and AccountsPRICE SENSITIVE21/02/17
ACL Appendix 4C - QuarterlyPRICE SENSITIVE30/01/17
ACL Initial Director's Interest Notice13/12/16
ACL Appointment of Non-Executive Director13/12/16
ACL Results of Annual General Meeting25/11/16
ACL Final Director's Interest Notice25/11/16
ACL Resignation of Director and Withdrawal of AGM Resolution25/11/16
ACL Appendix 4C - Quarterly-ACL.AX PRICE SENSITIVE27/10/16
ACL Notice of Annual General Meeting/Proxy Form-ACL.AX 21/10/16
ACL Appendix 4G and Corporate Governance Statement-ACL.AX 30/08/16
ACL Appendix 4E and 2016 Annual Report-ACL.AX PRICE SENSITIVE30/08/16
ACL Appendix 4C - Quarterly-ACL.AX PRICE SENSITIVE29/07/16
ACL Final Director's Interest Notice-ACL.AX 29/06/16
ACL Resignation of Non-Executive Director-ACL.AX 29/06/16
ACL Reinstatement to Official Quotation-ACL.AX PRICE SENSITIVE16/06/16
ACL Update on Company Activities-ACL.AX PRICE SENSITIVE16/06/16
ACL Company Update-ACL.AX 15/06/16
ACL Suspension from Official Quotation at close of trading-ACL.AX PRICE SENSITIVE14/06/16
ACL Appendix 4C - Quarterly-ACL.AX PRICE SENSITIVE20/04/16
ACL Change of Company Secretary-ACL.AX 11/04/16
ACL Change in substantial holding10/03/16
ACL Becoming a substantial holder08/03/16
ACL Initial Director's Interest Notice08/03/16
ACL Non-Executive Director Appointment07/03/16
ACL Becoming a substantial holder04/03/16
ACL Ceasing to be a substantial holder from SNC29/02/16
ACL Initial Director's Interest Notice29/02/16
ACL Final Director's Interest Notice29/02/16
ACL Non-Executive Chairman appointment Non-Executive Chairman re29/02/16
ACL Half Yearly Report and AccountsPRICE SENSITIVE26/02/16
ACL Completion of Capital Return to Shareholders24/02/16
ACL Change in substantial holding from SNC03/02/16
ACL Ceasing to be a substantial holder02/02/16
ACL Update - Return of Capital - ACL28/01/16
ACL Appendix 4C - quarterlyPRICE SENSITIVE28/01/16
ACL Results of Meeting28/01/16
ACL Return of Capital - ACL22/12/15
ACL Cancel - Dividend/Distribution - ACL21/12/15
ACL Dividend/Distribution - ACL18/12/15
ACL Notice of General Meeting/Proxy FormPRICE SENSITIVE17/12/15
ACL General Meeting Announcement17/12/15
ACL ACL Receives $6.4m R&D Tax RefundPRICE SENSITIVE08/12/15
ACL Change in substantial holding from SNC20/11/15
ACL Completion of Fondaparinux Intellectual Property Sale18/11/15
ACL Change in substantial holding from SNC16/11/15
ACL Change in substantial holding13/11/15
ACL Change of Company Registered Address11/11/15
ACL Results of Meeting10/11/15
ACL Appendix 3B02/11/15
ACL Appendix 4C - quarterlyPRICE SENSITIVE28/10/15
ACL Change in substantial holding19/10/15
ACL Notice of Annual General Meeting/Proxy Form09/10/15
ACL Appendix 4G Corporate Governance Disclosures07/10/15
ACL Annual Report to shareholders07/10/15
ACL Change in substantial holding29/09/15
ACL Sale of Fondaparinux IPPRICE SENSITIVE25/09/15
ACL Alchemia Financial Results for year ended 201528/08/15
ACL Preliminary Final ReportPRICE SENSITIVE28/08/15
ACL Update on Conditional Sale of Oncology Subsidiary03/08/15
ACL Cash Result for the Quarter Ending 30 June 201531/07/15
ACL Appendix 4C - quarterlyPRICE SENSITIVE31/07/15
ACL Chairman Appointment10/07/15
ACL Final Director's Interest Notice09/07/15
ACL Retirement of Non-Executive Director09/07/15
ACL Withdrawal of Requisition of General Meeting06/07/15
ACL Ceasing to be a substantial holder from MS
19/09/24
ACL Ceasing to be a substantial holder
19/09/24
ACL Change in substantial holding from MUFG
19/09/24
ACL Change in substantial holding
19/09/24
ACL Becoming a substantial holder from MS
19/09/24
ACL Initial Director's Interest Notices x 2
05/03/19
ACL Final Director's Interest Notices x 2
05/03/19
ACL Changes to the Board of Directors
05/03/19
ACL Appendix 4D and Half Year Report
27/02/19PRICE SENSITIVE
ACL Appendix 4C - Quarterly
18/01/19PRICE SENSITIVE
ACL Results of Annual General Meeting
27/11/18
ACL Notice of Annual General Meeting/Proxy Form
26/10/18
ACL Appendix 4C - Quarterly
19/10/18PRICE SENSITIVE
ACL Response to ASX Price Query
17/10/18PRICE SENSITIVE
ACL Appendix 4G and Corporate Governance Statement
30/08/18
ACL Appendix 4E and 2018 Annual Report
30/08/18PRICE SENSITIVE
ACL Appendix 4C - Quarterly
23/07/18PRICE SENSITIVE download Created with Sketch. 198.16KB
ACL Final Director's Interest Notice
06/06/18 download Created with Sketch. 152.41KB
ACL Initial Director's Interest Notice
06/06/18 download Created with Sketch. 154.9KB
ACL Changes to the Board of Directors
06/06/18 download Created with Sketch. 166.79KB
ACL Response to ASX Price Query
09/05/18PRICE SENSITIVE
ACL Appendix 4C - Quarterly
24/04/18PRICE SENSITIVE
ACL Appendix 4D and Half Year Report
21/02/18PRICE SENSITIVE
ACL Appendix 4C - Quarterly
25/01/18PRICE SENSITIVE
ACL Ceasing to be a substantial holder
08/01/18
ACL Change of Director's Interest Notices x2
08/01/18
ACL Response to ASX Price Query
03/01/18PRICE SENSITIVE
ACL Results of Annual General Meeting
28/11/17
ACL Appendix 4C - Quarterly
27/10/17PRICE SENSITIVE
ACL Notice of Annual General Meeting/Proxy Form
25/10/17
ACL Appendix 4G and Corporate Governance Statement
23/08/17
ACL Appendix 4E and 2017 Annual Report
23/08/17PRICE SENSITIVE
ACL Appendix 4C - Quarterly
27/07/17PRICE SENSITIVE
ACL Change of Director's Interest Notice
07/07/17
ACL Appendix 4C - Quarterly
26/04/17PRICE SENSITIVE
ACL Half Yearly Report and Accounts
21/02/17PRICE SENSITIVE
ACL Appendix 4C - Quarterly
30/01/17PRICE SENSITIVE
ACL Initial Director's Interest Notice
13/12/16
ACL Appointment of Non-Executive Director
13/12/16
ACL Results of Annual General Meeting
25/11/16
ACL Final Director's Interest Notice
25/11/16
ACL Resignation of Director and Withdrawal of AGM Resolution
25/11/16
ACL Appendix 4C - Quarterly-ACL.AX
27/10/16PRICE SENSITIVE
ACL Notice of Annual General Meeting/Proxy Form-ACL.AX
21/10/16
ACL Appendix 4G and Corporate Governance Statement-ACL.AX
30/08/16
ACL Appendix 4E and 2016 Annual Report-ACL.AX
30/08/16PRICE SENSITIVE
ACL Appendix 4C - Quarterly-ACL.AX
29/07/16PRICE SENSITIVE
ACL Final Director's Interest Notice-ACL.AX
29/06/16
ACL Resignation of Non-Executive Director-ACL.AX
29/06/16
ACL Reinstatement to Official Quotation-ACL.AX
16/06/16PRICE SENSITIVE
ACL Update on Company Activities-ACL.AX
16/06/16PRICE SENSITIVE
ACL Company Update-ACL.AX
15/06/16
ACL Suspension from Official Quotation at close of trading-ACL.AX
14/06/16PRICE SENSITIVE
ACL Appendix 4C - Quarterly-ACL.AX
20/04/16PRICE SENSITIVE
ACL Change of Company Secretary-ACL.AX
11/04/16
ACL Change in substantial holding
10/03/16
ACL Becoming a substantial holder
08/03/16
ACL Initial Director's Interest Notice
08/03/16
ACL Non-Executive Director Appointment
07/03/16
ACL Becoming a substantial holder
04/03/16
ACL Ceasing to be a substantial holder from SNC
29/02/16
ACL Initial Director's Interest Notice
29/02/16
ACL Final Director's Interest Notice
29/02/16
ACL Non-Executive Chairman appointment Non-Executive Chairman re
29/02/16
ACL Half Yearly Report and Accounts
26/02/16PRICE SENSITIVE
ACL Completion of Capital Return to Shareholders
24/02/16
ACL Change in substantial holding from SNC
03/02/16
ACL Ceasing to be a substantial holder
02/02/16
ACL Update - Return of Capital - ACL
28/01/16
ACL Appendix 4C - quarterly
28/01/16PRICE SENSITIVE
ACL Results of Meeting
28/01/16
ACL Return of Capital - ACL
22/12/15
ACL Cancel - Dividend/Distribution - ACL
21/12/15
ACL Dividend/Distribution - ACL
18/12/15
ACL Notice of General Meeting/Proxy Form
17/12/15PRICE SENSITIVE
ACL General Meeting Announcement
17/12/15
ACL ACL Receives $6.4m R&D Tax Refund
08/12/15PRICE SENSITIVE
ACL Change in substantial holding from SNC
20/11/15
ACL Completion of Fondaparinux Intellectual Property Sale
18/11/15
ACL Change in substantial holding from SNC
16/11/15
ACL Change in substantial holding
13/11/15
ACL Change of Company Registered Address
11/11/15
ACL Results of Meeting
10/11/15
ACL Appendix 3B
02/11/15
ACL Appendix 4C - quarterly
28/10/15PRICE SENSITIVE
ACL Change in substantial holding
19/10/15
ACL Notice of Annual General Meeting/Proxy Form
09/10/15
ACL Appendix 4G Corporate Governance Disclosures
07/10/15
ACL Annual Report to shareholders
07/10/15
ACL Change in substantial holding
29/09/15
ACL Sale of Fondaparinux IP
25/09/15PRICE SENSITIVE
ACL Alchemia Financial Results for year ended 2015
28/08/15
ACL Preliminary Final Report
28/08/15PRICE SENSITIVE
ACL Update on Conditional Sale of Oncology Subsidiary
03/08/15
ACL Cash Result for the Quarter Ending 30 June 2015
31/07/15
ACL Appendix 4C - quarterly
31/07/15PRICE SENSITIVE
ACL Chairman Appointment
10/07/15
ACL Final Director's Interest Notice
09/07/15
ACL Retirement of Non-Executive Director
09/07/15
ACL Withdrawal of Requisition of General Meeting
06/07/15
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$3.54 		Change
0.080(2.31%) 		Mkt cap ! $708.4M
Open High Low Value Volume
$3.50 $3.57 $3.47 $1.588M 449.5K

Buyers (Bids)

No. Vol. Price($)
3 4389 $3.52
 

Sellers (Offers)

Price($) Vol. No.
$3.55 4393 2
View Market Depth
Last trade - 16.10pm 03/12/2024 (20 minute delay) ?
Last
$3.53 		  Change
0.080 ( 2.68 %)
Open High Low Volume
$3.48 $3.56 $3.47 1326302
Last updated 15.59pm 03/12/2024 ?
ACL (ASX) Chart

Top Stories

Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising!

Companies can now raise capital through HotCopper! It’s a development allowing a highly cost-effective service to ASX-listed companies, while opening new investment opportunities to investors.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.